We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
New IDDI leaders announced!
Meet the new faces guiding PVRI’s Innovative Drug Discovery Initiative - Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio) join Sandeep Sahay and Luke Howard in the IDDI Leadership Team.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
The Sixth Pulmonary Hypertension International Hybrid Meeting is going to be held from 10 - 11 July 2025 on behalf of Tuberculosis and Lung diseases Research Center of Tabriz University of Medical Sciences and Iranian society of Pulmonology. This meeting will be held with collaboration of Iranian society of Heart Failure.
Part of the Latin America Task Force new webinar series, this session aims to evaluate PH and differential diagnosis, and the differences in phenotype presentations in Latin America and USA / Europe.
PAH is classically described as a disease in young adults, with no comorbidities. However, recent registries showed the epidemiology has changed to older patients with comorbidities (obesity, diabetes, hypertension, and coronary heart disease). In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present with a different phenotype.
Pulmonary arterial hypertension (PAH) Group 1 from the World Health Organization (WHO) is a rare, severe chronic, and progressive condition. Patients with PAH have increased oxidative stress (OS) and diminished antioxidant capacity. Melatonin is a potent antioxidant hormone with reported benefits in PAH animal models.
Cardiac output is essential to calculate pulmonary vascular resistance (PVR) and classify pulmonary hypertension (PH). Recent evidence has shown a lower agreement between thermodilution (COTD) and direct Fick (CODF) methods than historically estimated. The influence of the cardiac output measurement method on the classification of PH is poorly explored.
While anxiety and depression are commonly reported in pulmonary hypertension (PH), limited evidence exists on how these conditions interact with the pathophysiological symptoms of PH. Fatigue and, to a lesser degree, pain are key symptoms of PH; however, they have rarely been examined as separate experiences associated with PH.
Your feedback is needed on our work groups and subject areas...We’re reviewing some of our IDDI Workstream activity, and we need you to help us shape the future agenda.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
